Quantcast

Posts related to ‘Drug companies’

How the Election Cycle Will Win For TV & Media (GCI, SSP, JRN, GTN, SBGI, BLC)

Posted: June 16, 2011 at 10:50 am

Gabelli & Co. has a unique research report out this morning and we took a look at this to see where the opportunity is.  Imagine that television stocks should still ...
Read Full Story »

Beyond the Pharma Patent Cliff, Dividends Galore (LLY, BMY, MRK, PFE, ABT)

Posted: June 16, 2011 at 8:10 am

Many drug companies face a what is called a patent cliff ahead, where the Big Pharma players will have key drugs go off-patent and there will be new generic competition.  ...
Read Full Story »

M&A Watch: Biotech Deals Keep Rolling, Who Is The Next Buyout Target? (TEVA, VRX, CEPH, CRA, ALXN, DNDN, CBST, HGSI, UTHR, CADX, AMAG, SGMO)

Posted: May 2, 2011 at 7:46 pm

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has trumped Valeant Pharmaceuticals International, Inc. (NYSE: VRX) after it agreed to acquire Cephalon Inc. (NASDAQ: CEPH) in a $6.8 billion deal.  The merger will give ...
Read Full Story »

Dividend Watch: Lilly Highlights Drug Sector Dividends Ahead of Earnings Season (LLY, PFE, MRK, AZN, GSK)

Posted: April 18, 2011 at 11:01 am

The drug sector has become rather boring and investors already know all about the ongoing patent expiration threats that loom in the industry.  The good news is that the drug ...
Read Full Story »

BioWatch: Amarin Joins Ten-Bagger Chase (AMRN)

Posted: April 18, 2011 at 9:17 am

Amarin Inc. (NASDAQ: AMRN) just went off the charts, literally.  The company reported very solid Phase III study results this morning and the stock is now up almost tenfold from ...
Read Full Story »

BioWatch: Dendreon Looks Even Brighter (DNDN)

Posted: April 1, 2011 at 12:17 pm

Earlier this week, we highlighted Dendreon Corporation (NASDAQ: DNDN) as one of five biotechs with 50% implied upside.  A new report is out from Canaccord Genuity that has figures which ...
Read Full Story »

DrugWatch: K-V Tries a Do-Over Approach on Makena (KV-A)

Posted: March 31, 2011 at 8:55 am

When we first covered K-V Pharmaceutical Co. (NYSE: KV-A) for its Makena drug market exclusivity to prevent premature birth, we knew this was going to be a home run.  But ...
Read Full Story »

BioWatch: Biotechs With 50% Implied Upside (GENZ, CEPH, ALNY, DNDN, GERN, HALO, VVUS)

Posted: March 30, 2011 at 10:48 am

Biotech is about to become even less of a diversified sector due to mergers and acquisitions. Genzyme Corporation (NASDAQ: GENZ) and Cephalon Inc. (NASDAQ: CEPH) will end up accounting for ...
Read Full Story »

BioHealth Watch: Cancer Wars (BMY, DNDN, VICL)

Posted: March 28, 2011 at 10:01 am

The fight against melanoma just got a new weapon after a drug called Yervoy, or ipilimumab, was given FDA approval for late-stage metastatic melanoma.  The approval is a win for ...
Read Full Story »

The 10 Companies That Will Save The American Economy

Posted: March 25, 2011 at 4:31 am

America lost its lead as the world’s top manufacturer to China. That is in part the basis of the argument that China’s Gross Domestic Product will pass America’s sometime before ...
Read Full Story »

M&A Daily: Is Drugstore.com Worth the Price? (WAG, CHSI, DSCM)

Posted: March 24, 2011 at 12:27 pm

It was not that long ago that Walgreen Co. (NYSE: WAG) sold off its PBM unit to Catalyst Health Solutions, Inc. (NASDAQ: CHSI).  The deal was valued around $525 million, ...
Read Full Story »

Daily Dividend: Will Amgen Finally Start Paying Shareholders? (AMGN, PFE, MRK)

Posted: March 24, 2011 at 11:10 am

It is time for "The Daily Dividend" and we have an interesting call ahead.  How long has it been that Amgen Inc. (NASDAQ: AMGN) has been touted as a "Should Be" ...
Read Full Story »

BioHealth Daily: Death of Xoma May Be Premature (XOMA)

Posted: March 23, 2011 at 10:09 am

Xoma Ltd. (NASDAQ: XOMA) is getting crushed this morning on news that its potential Type-2 diabetes drug failed to lower blood sugar levels.  The news is bad, but there are a ...
Read Full Story »

BioHealth Daily: Forgetting Alzheimers (PRAN, PFE, NVS, FRX)

Posted: March 22, 2011 at 9:39 am

It's the BioHeath Daily for key developments in drugs, biotech, and medical developments.  Prana Biotechnology Ltd. (NASDAQ: PRAN) is often overlooked here in the U.S. as it has such a ...
Read Full Story »

Daily M&A Outlook: Rethinking Human Genome Sciences as Target (HGSI, GSK)

Posted: March 10, 2011 at 12:06 pm

As you would expect now that Benlysta has been approved as the first Lupus treatment in more than 50 years, some investors are wondering and perhaps hoping that Human Genome ...
Read Full Story »